Department of clinical laboratory, Quzhou Kecheng People's Hospital, Quzhou 32400, Zhejiang, China.
Cell Mol Biol (Noisy-le-grand). 2022 Feb 4;67(5):109-116. doi: 10.14715/cmb/2021.67.5.15.
This study aimed to investigate the clinical significance of the detection of mononuclear phagocytes subsets in pulmonary sarcoidosis blood and bronchoalveolar lavage fluid (BALF). For this purpose, a total of 52 patients with pulmonary sarcoidosis were selected as the study group, 52 healthy people served as the "NC Group a" (peripheral blood mononuclear cell control group), 47 patients with chronic cough and no pulmonary sarcoidosis who underwent bronchoscopy were used as "control group b" (alveolar lavage fluid macrophage control group). Fasting peripheral blood and BALF were collected, and flow cytometry was used to detect monocytes and macrophage subpopulations. The monocytes and macrophage subpopulations of the study group were compared before and after treatment. The results showed that the proportion of CD14++CD16- subgroup of patients with pulmonary sarcoidosis was lower than that of healthy people (74.21±4.10% vs 84.32±4.76%); The proportion of CD14++CD16+ subgroups of patients with pulmonary sarcoidosis was higher than that of healthy people (7.42±4.08% vs 3.95±1.94%); The proportion of CD14+CD16++ subgroups of patients with pulmonary sarcoidosis was higher than that of healthy people in the control group, but the difference was not significant. After 2 months of treatment, the proportion of CD14++CD16- subgroups in peripheral blood mononuclear cells increased, and the proportion of CD14++CD16+ subgroups decreased. The proportion of M1 in patients with pulmonary sarcoidosis was lower than that in patients with non-pulmonary nodules (24.32±11.36% vs 47.03±13.86%); the proportion of M2 in patients with pulmonary sarcoidosis was higher than the proportion of M2 in patients with non-pulmonary nodules (75.40±10.23% vs 52.53±12.01%). After treatment, the proportion of M1 of BALF macrophages in patients with pulmonary sarcoidosis was increased (P<0.05), and the proportion of M2 was reduced (P<0.05). In general, detection of changes in peripheral blood mononuclear cell subpopulations and BALF macrophage subpopulations in patients with pulmonary sarcoidosis has certain clinical significance for the treatment.
本研究旨在探讨检测肺结节病患者血液和支气管肺泡灌洗液(BALF)中单核细胞亚群的临床意义。为此,选择了 52 例肺结节病患者作为研究组,52 名健康人作为“NC 组 a”(外周血单个核细胞对照组),47 例因慢性咳嗽且无肺结节病而行支气管镜检查的患者作为“对照组 b”(肺泡灌洗液巨噬细胞对照组)。采集空腹外周血和 BALF,采用流式细胞术检测单核细胞和巨噬细胞亚群。比较治疗前后研究组患者的单核细胞和巨噬细胞亚群。结果显示,肺结节病患者的 CD14++CD16-亚群比例低于健康人(74.21±4.10% vs 84.32±4.76%);肺结节病患者的 CD14++CD16+亚群比例高于健康人(7.42±4.08% vs 3.95±1.94%);肺结节病患者的 CD14+CD16++亚群比例高于对照组健康人,但差异无统计学意义。治疗 2 个月后,外周血单个核细胞 CD14++CD16-亚群比例增加,CD14++CD16+亚群比例下降。肺结节病患者 M1 比例低于非肺结节患者(24.32±11.36% vs 47.03±13.86%);肺结节病患者 M2 比例高于非肺结节患者(75.40±10.23% vs 52.53±12.01%)。治疗后,肺结节病患者 BALF 巨噬细胞 M1 比例增加(P<0.05),M2 比例降低(P<0.05)。总之,检测肺结节病患者外周血单个核细胞亚群和 BALF 巨噬细胞亚群的变化对治疗具有一定的临床意义。